Sanofi signs agreement worth up to $750m for Maze's Pompe disease drug
Sanofi Genzyme: COMET Phase 3 Trial - Results | Pompe Support Network
Sanofi pumps up its Pompe portfolio with Maze deal | Evaluate
Sanofi terminates deal to exclusively license Maze Therapeutics Pompe disease drug
FDA aprueba Nexviazyme® de Sanofi Genzyme, una nueva e importante opción de tratamiento para la enfermedad de Pompe
Sanofi strengthens in Pompe disease with Maze tie-up
Sanofi Genzyme goes to Phase III with Neuromuscular Disease
FDA approves Sanofi's Nexviazyme for late-onset Pompe disease - Drug Discovery and Development
Sanofi Italia on X: "La nostra ricerca sulle malattie rare non si ferma: sono 39 le presentazioni che terremo in questi giorni al @WORLDSymposia 2022 a San Francisco. Tra queste, anche nuovi
MeetSanofi | Malattia di Pompe, la qualità della vita passa anche dal cibo e dalla tecnologia
Sanofi drops acquisition of Maze's Pompe Disease drug after FTC challenge - PharmaLive
Sanofi: forte crescita delle vendite nel 2021 - Tecnomedicina
DottNet - Malattia di Pompe: priority review della FDA per avalglucosidasi alfa
Compelling Evidence - Havas Lynx Group
Sanofi Aventis – GM IMPIANTI
Pompe - Climbing Stairs
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug - MedCity News
Sanofi termina l'accordo sulla licenza del farmaco dopo le obiezioni della FTC statunitense -11 dicembre 2023 alle 22:33 | MarketScreener
Sanofi US on X: "Have you heard of #Pompe disease? Just knowing the symptoms of this #RareDisease could help reduce the time to diagnosis. Share with the hashtag #GreaterThanPompe to raise awareness
European Commission Approves Sanofi Enzyme Replacement Therapy for Pompe Disease - Global Genes
Sanofi Genzyme: The Compelling Evidence of Pompe - Stand Up, Reach Up, Give Up • Ads of the World™ | Part of The Clio Network
Malattie rare, le tre 'direzioni' dell'impegno di Sanofi - Osservatorio Malattie Rare
Sanofi stock rises on licensing deal with Maze for Pompe disease drug | Seeking Alpha
Sanofi Deepens Pompe Disease Focus with $150M Maze Partnership | BioSpace
Sanofi su LinkedIn: Malattia di Fabry
